Clinical trial · Observational
The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer
The Role of ctDNA and PBMC as Biomarkers in Diagnostic, Efficacy Monitoring and Prognostic Evaluation of Biliary Tract Cancer
NCT02809898CI-TRIAL-00041185unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Neoplasms | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| surgery or biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）
- timeFrame
- intraoperative
- description
- Sensitivity and specificity
Secondary outcomes (1)
- measure
- Tumor status （worse/ maintain/ better）
- timeFrame
- 3 years
- description
- the level of ct-DNA compared with the tumor burden
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with suspected biliary tract cancer * Age from 18 - 70 years * No serious organic and mental illness; Exclusion Criteria: * Pregnancy * No pathologic result * Suffering other malignancies at the same time.
References
Publications (0)
Data not yet available
No reference posted for this study.